Futura Medical PLC Director/PDMR Shareholding (8723M)

TIDMFUM

RNS Number : 8723M

Futura Medical PLC

18 September 2019

Directors' / PDMR Dealing and Grant of Options

18 September 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology currently focused on sexual health and pain, today announces that on 17 September 2019 it made its annual grant of options over a total of 1,400,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to employees and Directors, of which 650,000 options were granted to Directors and PDMRs as detailed below.

 
                                                        Total number 
                  Number                                  of options  Total number 
              of options  Exercise                    held following   of Ordinary 
Director         granted     price  Exercise period     notification   Shares held 
-----------  -----------  --------  ---------------  ---------------  ------------ 
 
                                    1 Oct 2021 - 30 
J H Barder       250,000       31p         Sep 2026        1,750,000     1,085,972 
 
                                    1 Oct 2021 - 30 
A Hildreth       200,000       31p        Sept 2026          400,000       142,857 
 
                                    1 Oct 2021 - 30 
K W James        200,000       31p        Sept 2026          800,000       299,581 
 

Of the total 1,400,000 options, 1,281,935 were granted under the Futura Medical plc Enterprise Management Incentive Scheme, and 118,065 were granted under the unapproved scheme.

The main vesting condition of the options is that the Director/PDMR/employee remains employed with the Company as at the date of exercise. Further disclosures are contained in the tables below.

S 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

Nominated Adviser and Broker:

Liberum

Bidhi Bhoma/ Euan Brown/ Kane Collings

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel: [phone]

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with a 450 patient open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             James Barder 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Chief Executive Officer 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Futura Medical plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              21380053QLT46UNV2303 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.2 pence each 
       financial instrument, 
       type of instrument 
                                        GB0033278473 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Grant of options over Ordinary Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)               Price(s)       Volume(s) 
                                         Exercise price 
                                          of 
                                          31 pence         250,000 
                                                          ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information           N/A single transaction 
       - Aggregated volume 
       - Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          17 September 2019 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Angela Hildreth 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Finance Director and 
                                        Chief Operating Officer 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Futura Medical plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              21380053QLT46UNV2303 
     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.2 pence each 
       financial instrument, 
       type of instrument 
                                        GB0033278473 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Grant of options over Ordinary Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)               Price(s)       Volume(s) 
                                         Exercise price 
                                          of 
                                          31 pence         200,000 
                                                          ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information           N/A single transaction 
       - Aggregated volume 
       - Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          17 September 2019 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Ken James 
     -------------------------------  -------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Executive Director 
                                        and Head of R&D 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             Futura Medical plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              21380053QLT46UNV2303 

     -------------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 0.2 pence each 
       financial instrument, 
       type of instrument 
                                        GB0033278473 
       Identification code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the transaction        Grant of options over Ordinary Shares 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)               Price(s)       Volume(s) 
                                         Exercise price 
                                          of 
                                          31 pence         200,000 
                                                          ---------- 
     -------------------------------  -------------------------------------- 
 d)   Aggregated information           N/A single transaction 
       - Aggregated volume 
       - Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          17 September 2019 
     -------------------------------  -------------------------------------- 
 f)   Place of the transaction         Outside a trading venue 
     -------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLLFSRALITLIA

(END) Dow Jones Newswires

September 18, 2019 12:42 ET (16:42 GMT)